• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Fate Therapeutics

edit

Founded in 2007 on the leading stem cell and developmental biology research, Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics. The company has brought together the foremost scientists from the nation’s research hotbeds (Boston, San Francisco, San Diego and Seattle) who have demonstrated the potential to create and modulate stem cells to restore health.

Milestones

edit

• 
  Fate Therapeutics added William Rastetter as Chairman & Interim CEO.
  Posted 12/14/11 at 6:56pm
• 
  Fate Therapeutics added Francine Farouz as Senior Director Medicinal Chemisty.
  Posted 11/16/09 at 11:35am
• 
  Fate Therapeutics added Scott Thies as Senior Director Stem Cell Biology.
  Posted 11/16/09 at 11:35am
• 
  Fate Therapeutics added Pratik Multani as SVP Clinical Development.
  Posted 11/16/09 at 11:35am
• 
  Fate Therapeutics added Scott Wolchko as CFO & Vice President of Operations.
  Posted 11/16/09 at 11:35am
• 
  Fate Therapeutics added Dan Shoemaker as CTO.
  Posted 11/16/09 at 11:35am
• 
  Fate Therapeutics added Paul Grayson as President, CEO.
  Posted 11/16/09 at 11:35am
• 
  Fate Therapeutics received $12M in Series A funding. (11/29/07)
  Posted 11/16/09 at 11:35am via bizjournals.com
• 
  Fate Therapeutics received $30M in Series B funding. (11/16/09)
  Posted 11/16/09 at 11:35am via fatetherapeutics.com

Videos

Screenshots

edit

Above: Home Page
Uploaded: 3/13/10

Sources

1. Puget Sounds Business Journal (seattle.bizjournals.com) [edit]
2. Fate Therapetucis (fatetherapeutics.com) [edit]